WO2007075980A8 - Comprimes de lansoprazole se desintegrant oralement - Google Patents

Comprimes de lansoprazole se desintegrant oralement

Info

Publication number
WO2007075980A8
WO2007075980A8 PCT/US2006/048961 US2006048961W WO2007075980A8 WO 2007075980 A8 WO2007075980 A8 WO 2007075980A8 US 2006048961 W US2006048961 W US 2006048961W WO 2007075980 A8 WO2007075980 A8 WO 2007075980A8
Authority
WO
WIPO (PCT)
Prior art keywords
orally disintegrating
disintegrating tablets
lansoprazole
tablets
lansoprazole orally
Prior art date
Application number
PCT/US2006/048961
Other languages
English (en)
Other versions
WO2007075980A2 (fr
WO2007075980A3 (fr
Inventor
David Isaac Silver
Limor Ari-Pardo
Sivan Antler
Nava Shterman
Capua Simona Di
Original Assignee
Teva Pharma
David Isaac Silver
Limor Ari-Pardo
Sivan Antler
Nava Shterman
Capua Simona Di
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/314,656 external-priority patent/US20070141151A1/en
Priority claimed from EP05257891A external-priority patent/EP1813275A1/fr
Priority claimed from PCT/US2005/046296 external-priority patent/WO2007078271A2/fr
Application filed by Teva Pharma, David Isaac Silver, Limor Ari-Pardo, Sivan Antler, Nava Shterman, Capua Simona Di filed Critical Teva Pharma
Priority to EP06848925A priority Critical patent/EP1962844A2/fr
Priority to CA002633825A priority patent/CA2633825A1/fr
Priority to JP2008547591A priority patent/JP2009524592A/ja
Publication of WO2007075980A2 publication Critical patent/WO2007075980A2/fr
Publication of WO2007075980A3 publication Critical patent/WO2007075980A3/fr
Priority to IL191923A priority patent/IL191923A0/en
Publication of WO2007075980A8 publication Critical patent/WO2007075980A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des comprimés qui se dissolvent facilement dans la bouche pour libérer le médicament contenu dans les comprimés entériques intérieurs enrobés.
PCT/US2006/048961 2005-12-20 2006-12-20 Comprimes de lansoprazole se desintegrant oralement WO2007075980A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP06848925A EP1962844A2 (fr) 2005-12-20 2006-12-20 Comprime oral desintegrable de lansoprazole
CA002633825A CA2633825A1 (fr) 2005-12-20 2006-12-20 Comprimes de lansoprazole se desintegrant oralement
JP2008547591A JP2009524592A (ja) 2005-12-20 2006-12-20 ランソプラゾール経口崩壊錠剤
IL191923A IL191923A0 (en) 2005-12-20 2008-06-03 Lansoprazole orally disintegrating tablets

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11/314,656 US20070141151A1 (en) 2005-12-20 2005-12-20 Lansoprazole orally disintegrating tablets
EP05257891A EP1813275A1 (fr) 2005-12-20 2005-12-20 Comprime oral desintegrable de lansoprazole
US11/314,656 2005-12-20
PCT/US2005/046296 WO2007078271A2 (fr) 2005-12-20 2005-12-20 Comprimes a desintegration orale de lansoprazole
USPCT/US05/46296 2005-12-20
EP05257891.1 2005-12-20

Publications (3)

Publication Number Publication Date
WO2007075980A2 WO2007075980A2 (fr) 2007-07-05
WO2007075980A3 WO2007075980A3 (fr) 2008-02-21
WO2007075980A8 true WO2007075980A8 (fr) 2008-07-17

Family

ID=38218650

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/048961 WO2007075980A2 (fr) 2005-12-20 2006-12-20 Comprimes de lansoprazole se desintegrant oralement

Country Status (5)

Country Link
EP (1) EP1962844A2 (fr)
JP (1) JP2009524592A (fr)
CA (1) CA2633825A1 (fr)
IL (1) IL191923A0 (fr)
WO (1) WO2007075980A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044929A1 (fr) * 2007-10-04 2009-04-08 Laboratorios del Dr. Esteve S.A. Comprimés oraux à désintégration rapide
WO2009113090A2 (fr) * 2008-01-17 2009-09-17 Alkem Laboratories Ltd. Procédé de préparation d’une formule orale d’un médicament à base de benzimidazole sensible à l’acide
CN104127368A (zh) 2008-03-11 2014-11-05 武田药品工业株式会社 口腔崩解固体制剂
CN101507718B (zh) * 2009-03-03 2011-05-04 张登科 雷贝拉唑钠肠溶口崩片及其制备方法
FR2949061B1 (fr) * 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
WO2011111027A2 (fr) * 2010-03-11 2011-09-15 Dexcel Pharma Technologies Ltd. Formulation de comprimé oral dispersible à libération retardée
WO2012111024A1 (fr) * 2011-02-18 2012-08-23 Suven Nishtaa Pharma Pvt Ltd Compositions pharmaceutiques de dexlansoprazole
JP2020055755A (ja) * 2018-09-28 2020-04-09 日本ケミファ株式会社 腸溶性製剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
ATE262332T1 (de) * 1995-09-21 2004-04-15 Pharma Pass Ii Llc Lansoprazolhaltige arzneizusammensetzung und herstellungsverfahren
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
ES2559766T3 (es) * 1998-05-18 2016-02-15 Takeda Pharmaceutical Company Limited Comprimidos disgregables en la boca
US20050214372A1 (en) * 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug

Also Published As

Publication number Publication date
EP1962844A2 (fr) 2008-09-03
WO2007075980A2 (fr) 2007-07-05
WO2007075980A3 (fr) 2008-02-21
JP2009524592A (ja) 2009-07-02
CA2633825A1 (fr) 2007-07-05
IL191923A0 (en) 2009-08-03

Similar Documents

Publication Publication Date Title
WO2007078271A3 (fr) Comprimes a desintegration orale de lansoprazole
EG25188A (en) Device for the packaging and dispensing of solid shaped bodies, especially oral tablets or/and capsules.
ZA200704661B (en) Solid, orally appliance pharmaceutical administration forms containing rivaroxaban having modified release
WO2007075980A8 (fr) Comprimes de lansoprazole se desintegrant oralement
CA119221S (en) Blister package
AP2274A (en) Alcohol resistant dosage forms.
TNSN08071A1 (en) Solid dosage forms of valsartan and amlodipine and method of making the same
WO2006138503A8 (fr) Nouveaux schémas posologiques pour contraceptifs oraux monophasiques
TNSN08538A1 (en) Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same
BRPI0820997A2 (pt) Comprimidos de desintegração oral compreendendo difenidramina.
GB0419849D0 (en) Pharmaceutical combination
AP2239A (en) Direct currency conversion.
CA119774S (en) Blister package
CA118307S (en) Pasta dispenser disk
ZA200900673B (en) 18-methyl-19-nor-androst-4-en-17, 17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-one) and pharmaceutical preparations containing the same
HK1122218A1 (en) Anticancer concomitant drug
WO2007007182A3 (fr) Formes galeniques solides d'agent antiepileptique
AP2343A (en) Rapidly disintegrating taste-masked tablet.
ZA200408787B (en) Pharmaceutical combination.
GB2434894B8 (en) Triangular asynchronous replication.
CA116344S (en) Container for chewing gum
GB0417777D0 (en) Pharmaceutical combination
GB0502561D0 (en) The pill popper
ZA200501065B (en) The availability of commodities.
CA116159S (en) Pill case

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006848925

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2633825

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008547591

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 5361/DELNP/2008

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06848925

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 200680053033.6

Country of ref document: CN